PT  - JOURNAL ARTICLE
AU  - Vijaiganesh Nagarajan
AU  - Mohammed Chamsi-Pasha
AU  - W. H. Wilson Tang
TI  - The role of aldosterone receptor antagonists in the management of heart failure: An update
AID  - 10.3949/ccjm.79a.12014
DP  - 2012 Sep 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 631--639
VI  - 79
IP  - 9
4099  - http://www.ccjm.org/content/79/9/631.short
4100  - http://www.ccjm.org/content/79/9/631.full
SO  - Cleve Clin J Med2012 Sep 01; 79
AB  - The aldosterone receptor antagonists (ARAs) spironolactone (Aldactone) and eplerenone (Inspra) have become part of standard medical therapy for heart failure, having shown clinical efficacy in randomized trials in patients with advanced symptomatic systolic heart failure, postinfarction heart failure with cardiac dysfunction, and systolic heart failure with mild symptoms. The benefits include a lower rate of death. Yet to be answered is whether the two drugs are clinically equivalent; another question is whether they may benefit everyone with symptomatic heart failure, including diastolic heart failure.